Search research articles
Contact Us
Filters
Showing results (121-130 of 264) with videos related to
Page
of 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2011
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
Animesh Pardanani, Jason R Gotlib, Catriona Jamieson, et al.
Blood
|
May 20, 2006
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Disease Models & Mechanisms
|
March 30, 2022
Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation
Xi Jin, Victor Ng, Meiling Zhao, et al.
Ejhaem
|
June 19, 2025
Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials
Ruben A Mesa, Moshe Talpaz, Flora Mazerolle, et al.
Magnetic Resonance in Medicine
|
January 29, 2026
On-Scanner Correction of Gradient Nonlinearity Bias for Accurate Assessment of Diffusion Heterogeneity Across Bone Sites in Myelofibrosis Patients
Dariya Malyarenko, Brian D Ross, Johannes M Peeters, et al.
Blood Advances
|
August 2, 2023
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
Vikas Gupta, John Mascarenhas, Marina Kremyanskaya, et al.
Nature Communications
|
February 16, 2017
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma
Harish Potu, Luke F Peterson, Malathi Kandarpa, et al.
Haematologica
|
August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
Gautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Jorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
Cancer
|
May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
Jorge Cortes, Francis Giles, Susan O'Brien, et al.
Page
of 27
Search research articles
Search
Showing results (121-130 of 264) with videos related to
Sort By:
Page
of 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2011
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
Animesh Pardanani, Jason R Gotlib, Catriona Jamieson, et al.
Blood
|
May 20, 2006
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
Hagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Disease Models & Mechanisms
|
March 30, 2022
Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation
Xi Jin, Victor Ng, Meiling Zhao, et al.
Ejhaem
|
June 19, 2025
Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials
Ruben A Mesa, Moshe Talpaz, Flora Mazerolle, et al.
Magnetic Resonance in Medicine
|
January 29, 2026
On-Scanner Correction of Gradient Nonlinearity Bias for Accurate Assessment of Diffusion Heterogeneity Across Bone Sites in Myelofibrosis Patients
Dariya Malyarenko, Brian D Ross, Johannes M Peeters, et al.
Blood Advances
|
August 2, 2023
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
Vikas Gupta, John Mascarenhas, Marina Kremyanskaya, et al.
Nature Communications
|
February 16, 2017
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma
Harish Potu, Luke F Peterson, Malathi Kandarpa, et al.
Haematologica
|
August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
Gautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Jorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
Cancer
|
May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
Jorge Cortes, Francis Giles, Susan O'Brien, et al.
Page
of 27